...Fumio Ito; Nobuyuki Goya; Hayakazu Nakazawa; Toshiaki Suzuki; Keiko Suzuki; Kazuo Kubo; Takeshi Kihara Bicalutamide is an anti-androgen that is used worldwide to treat prostate cancer (CaP). However, there are no data on blood bicalutamide concentrations in hemodialysis (HD) patients with CaP...

...-independent disease. The aim of the present study was to compare gene expression changes that occur after treatment with either the antiandrogen bicalutamide or the 5-α-reductase inhibitors finasteride (MK906) and MK386. Materials and Methods: LNCaP cells of low passages were treated with MK906 and MK386 at 5...

...Mar Lefort; Manuel Díaz Curiel; María-Teresa Carrascal; Cioly Méndez-Dávila; Concepción de la Piedra Introduction: The aim of this work was to analyze the effects produced on bone mineral density (BMD) by the administration of bicalutamide and to compare them with those produced by orchidectomy...

... bicalutamide (50 mg once daily) plus either goserelin acetate or surgical castration for 48 weeks. Cox’s proportional hazard analysis was used to determine whether the decline of PSA following the use of this combination is predictive of a delay in progression. Results: PSA levels at weeks 4 and 12 were...

... cells showed a biphasic hypersensitive response to androgenic stimulation. Passages later than 75 are inhibited by androgen. Proliferation of LNCaP-abl cells was stimulated by the pure nonsteroidal antiandrogen bicalutamide (Casodex). To improve our understanding of changes which occur during...